Brokers Set Expectations for X4 Pharmaceuticals, Inc.’s Q2 2024 Earnings (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Analysts at HC Wainwright lowered their Q2 2024 earnings per share (EPS) estimates for shares of X4 Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 30th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.24) for the quarter, down from their previous forecast of ($0.20). HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.41) EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.05.

X4 Pharmaceuticals Stock Down 2.3 %

NASDAQ:XFOR opened at $1.08 on Thursday. X4 Pharmaceuticals has a one year low of $0.57 and a one year high of $2.58. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.34 and a quick ratio of 5.34. The company has a market cap of $181.38 million, a PE ratio of -1.80 and a beta of 0.51. The firm’s 50 day simple moving average is $1.16 and its 200 day simple moving average is $0.93.

Insider Activity

In other news, CEO Paula Ragan sold 49,678 shares of X4 Pharmaceuticals stock in a transaction on Monday, March 11th. The shares were sold at an average price of $0.88, for a total transaction of $43,716.64. Following the transaction, the chief executive officer now owns 765,068 shares in the company, valued at $673,259.84. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Paula Ragan sold 49,678 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $0.88, for a total transaction of $43,716.64. Following the completion of the transaction, the chief executive officer now directly owns 765,068 shares of the company’s stock, valued at approximately $673,259.84. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Adam S. Mostafa sold 27,721 shares of X4 Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $1.01, for a total value of $27,998.21. Following the transaction, the chief financial officer now directly owns 52,500 shares in the company, valued at $53,025. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 185,708 shares of company stock valued at $170,428. Insiders own 1.08% of the company’s stock.

Institutional Trading of X4 Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Kingdon Capital Management L.L.C. raised its holdings in X4 Pharmaceuticals by 76.0% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock worth $2,913,000 after purchasing an additional 1,500,000 shares during the last quarter. Bain Capital Life Sciences Investors LLC increased its position in shares of X4 Pharmaceuticals by 6.0% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company’s stock worth $14,184,000 after buying an additional 955,196 shares during the period. Stonepine Capital Management LLC increased its position in shares of X4 Pharmaceuticals by 14.5% during the third quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company’s stock worth $5,748,000 after buying an additional 668,422 shares during the period. GSA Capital Partners LLP bought a new position in X4 Pharmaceuticals during the third quarter worth $678,000. Finally, Barclays PLC lifted its holdings in X4 Pharmaceuticals by 334.8% in the third quarter. Barclays PLC now owns 382,134 shares of the company’s stock valued at $417,000 after buying an additional 294,255 shares during the period. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.